Cargando…

Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study

In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanimoto, Takuya, Tada, Shinpei, Fujita, Suguru, Hirakawa, Tetsu, Matsumura, Mirai, Isoyama, Shoko, Ueno, Sayaka, Hamai, Kosuke, Tsuji, Naoki, Hirosawa, Hideyasu, Taniguchi, Tomohiro, Okamoto, Takeshi, Omoto, Takuji, Kusunoki, Shinji, Maeda, Hiroyuki, Ishikawa, Nobuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Respiratory Society. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898743/
https://www.ncbi.nlm.nih.gov/pubmed/35307364
http://dx.doi.org/10.1016/j.resinv.2022.02.004
_version_ 1784663726456045568
author Tanimoto, Takuya
Tada, Shinpei
Fujita, Suguru
Hirakawa, Tetsu
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Hamai, Kosuke
Tsuji, Naoki
Hirosawa, Hideyasu
Taniguchi, Tomohiro
Okamoto, Takeshi
Omoto, Takuji
Kusunoki, Shinji
Maeda, Hiroyuki
Ishikawa, Nobuhisa
author_facet Tanimoto, Takuya
Tada, Shinpei
Fujita, Suguru
Hirakawa, Tetsu
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Hamai, Kosuke
Tsuji, Naoki
Hirosawa, Hideyasu
Taniguchi, Tomohiro
Okamoto, Takeshi
Omoto, Takuji
Kusunoki, Shinji
Maeda, Hiroyuki
Ishikawa, Nobuhisa
author_sort Tanimoto, Takuya
collection PubMed
description In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis.
format Online
Article
Text
id pubmed-8898743
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Respiratory Society. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88987432022-03-07 Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study Tanimoto, Takuya Tada, Shinpei Fujita, Suguru Hirakawa, Tetsu Matsumura, Mirai Isoyama, Shoko Ueno, Sayaka Hamai, Kosuke Tsuji, Naoki Hirosawa, Hideyasu Taniguchi, Tomohiro Okamoto, Takeshi Omoto, Takuji Kusunoki, Shinji Maeda, Hiroyuki Ishikawa, Nobuhisa Respir Investig Rapid Communication In this retrospective cohort study, we evaluated the efficacy of baricitinib in the treatment of coronavirus disease 2019 (COVID-19). Among 404 adult patients with COVID-19 who were admitted to our hospital between October 23, 2020, and July 31, 2021, 229 patients with respiratory failure were included. Among these, 41 patients in the baricitinib group and 41 patients in the control group were selected by propensity score matching to adjust for background factors. We compared the survival rates of the two groups at 30 and 60 days after admission. The 30-day survival rate was significantly higher in the baricitinib group than in the control group. However, there was no significant difference in 60-day survival in the two groups. Baricitinib may improve the early prognosis of patients with respiratory failure associated with COVID-19. However, efforts should be made to improve the long-term prognosis. The Japanese Respiratory Society. Published by Elsevier B.V. 2022-05 2022-03-07 /pmc/articles/PMC8898743/ /pubmed/35307364 http://dx.doi.org/10.1016/j.resinv.2022.02.004 Text en © 2022 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Rapid Communication
Tanimoto, Takuya
Tada, Shinpei
Fujita, Suguru
Hirakawa, Tetsu
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Hamai, Kosuke
Tsuji, Naoki
Hirosawa, Hideyasu
Taniguchi, Tomohiro
Okamoto, Takeshi
Omoto, Takuji
Kusunoki, Shinji
Maeda, Hiroyuki
Ishikawa, Nobuhisa
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title_full Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title_fullStr Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title_full_unstemmed Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title_short Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study
title_sort effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: a propensity score-matched retrospective cohort study
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898743/
https://www.ncbi.nlm.nih.gov/pubmed/35307364
http://dx.doi.org/10.1016/j.resinv.2022.02.004
work_keys_str_mv AT tanimototakuya effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT tadashinpei effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT fujitasuguru effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT hirakawatetsu effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT matsumuramirai effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT isoyamashoko effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT uenosayaka effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT hamaikosuke effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT tsujinaoki effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT hirosawahideyasu effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT taniguchitomohiro effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT okamototakeshi effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT omototakuji effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT kusunokishinji effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT maedahiroyuki effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy
AT ishikawanobuhisa effectofbaricitinibinpatientswithcoronavirusdisease2019andrespiratoryfailureapropensityscorematchedretrospectivecohortstudy